Profusa, Inc. (PFSA)
| Market Cap | 11.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.51M |
| Shares Out | 65.68M |
| EPS (ttm) | -2.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,354,081 |
| Open | 0.1591 |
| Previous Close | 0.1600 |
| Day's Range | 0.1500 - 0.1770 |
| 52-Week Range | 0.1159 - 12.7600 |
| Beta | -0.22 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2025 |
About PFSA
Profusa, Inc. develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California. [Read more]
Financial Performance
In 2024, Profusa's revenue was $100,000, an increase of 122.22% compared to the previous year's $45,000. Losses were -$9.23 million, -10.22% less than in 2023.
Financial StatementsNews
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO ₂) in peripheral artery disease patients BERKELEY, Calif, Nov. 24, 2025 (GLOBE NEWSWIRE) ...
Profusa Announces Third Quarter Business and Financial Highlights
Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target BERKELEY, Calif, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“P...
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches
EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform
Profusa Completes Manufacturing Build-Out, On Track to Begin Product Shipments and Revenue in Early 2026
Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets BERKELEY, Calif, Oct. 28, 2025 (GLOBE NEWSWIRE)...
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia
Profusa Invests Additional $1 Million in Digital Treasury Assets
BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform...
Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a comm...
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical workflows
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care
Profusa Announces Commercial and Clinical Collaboration with Head of Angiography, Medical University of Graz, Austria
Led by Prof. Dr. Marianne Brodmann, PI of clinical studies for the Lumee™ Oxygen CE Mark, collaboration includes practice adoption and platform integration in cases and clinical study programs
Profusa Welcomes Former Acting U.S. Veterans Affairs Secretary Peter O'Rourke as Lead Independent Director; Adds Seasoned Finance Executive Fred Knechtel as CFO
Board addition served in the Trump Administration, overseeing 1,300 facilities serving more than 9 million veterans; New CFO has led finance and operations at companies including Northrop Grumman, Sta...
Profusa, Inc. Provides Strategy Overview and Business Update for Investors
BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology pla...
Profusa Secures Lumee™ Oxygen Platform Distributor in Spain
BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology pla...
Profusa Announces $100 Million Equity Line of Credit to Initiate Bitcoin Treasury Strategy
BERKELEY, Calif, July 21, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology pla...
Profusa Announces Closing of Business Combination and the Commencement of Trading on Nasdaq
Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" BERKELEY, Calif, July 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Compa...